Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hyperlipoproteinemias
  Free Subscription

Articles published in
Atherosclerosis
    April 2024
  1. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
    Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Atherosclerosis. 2024;391:117476.
    >> Share

    March 2024
  2. REIJMAN MD, Kusters DM, Groothoff JW, Arbeiter K, et al
    Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
    Atherosclerosis. 2024;392:117525.
    >> Share

  3. ALONSO R, Arroyo-Olivares R, Diaz-Diaz JL, Fuentes-Jimenez F, et al
    Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516.
    >> Share

  4. ESCATE R, Padro T, Perez de Isla L, Fuentes F, et al
    Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients.
    Atherosclerosis. 2024;392:117502.
    >> Share

  5. SCHLEGEL A
    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.
    >> Share

    February 2024
  6. GUAY SP, Paquette M, Taschereau A, Girard L, et al
    Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Atherosclerosis. 2024 Feb 27:117489. doi: 10.1016/j.atherosclerosis.2024.117489.
    >> Share

    January 2024
  7. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    >> Share

    December 2023
  8. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    >> Share

  9. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.
    >> Share

  10. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    >> Share

    November 2023
  11. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    >> Share

  12. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    >> Share

  13. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    >> Share

  14. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    >> Share

    October 2023
  15. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.
    >> Share

  16. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    >> Share

  17. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    >> Share

  18. SANTOS RD
    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.
    >> Share

    September 2023
  19. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    >> Share

    August 2023
  20. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    >> Share

  21. HON A, Hsu JJ, Zambrano A, Xia Y, et al
    Effects of activity levels on aortic calcification in hyperlipidemic mice as measured by microPETmicroCT.
    Atherosclerosis. 2023;380:117198.
    >> Share

  22. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    >> Share

  23. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    >> Share

    July 2023
  24. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    >> Share

    June 2023
  25. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    >> Share

  26. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    >> Share

    May 2023
  27. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    >> Share

  28. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    >> Share

    April 2023
  29. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    >> Share

  30. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    >> Share

  31. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    >> Share

    March 2023
  32. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    >> Share

    December 2022
  33. FARIA R, Saramago P, Cox E, Weng S, et al
    How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.
    Atherosclerosis. 2022 Dec 29:S0021-9150(22)01557.
    >> Share

  34. KAMSTRUP PR
    Lipoprotein(a) and familial hypercholesterolemia: Partners in crime in heritable hyperlipidemia.
    Atherosclerosis. 2022 Dec 24:S0021-9150(22)01570.
    >> Share

  35. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Cardiovascular disease onset in old people with severe hypercholesterolemia.
    Atherosclerosis. 2022;365:9-14.
    >> Share

    November 2022
  36. TROMP TR, Ibrahim S, Nurmohamed NS, Peter J, et al
    Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.
    Atherosclerosis. 2022 Nov 29:S0021-9150(22)01530.
    >> Share

  37. HU YX, You HM, Zhu RF, Liang YL, et al
    Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
    Atherosclerosis. 2022;361:18-29.
    >> Share

    October 2022
  38. CEFALU AB, D'Erasmo L, Iannuzzo G, Noto D, et al
    Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Atherosclerosis. 2022;359:13-19.
    >> Share

    September 2022
  39. ZHU Q, Xiao Y, Jiang M, Liu X, et al
    N-acetylcysteine attenuates atherosclerosis progression in aging LDL receptor deficient mice with preserved M2 macrophages and increased CD146.
    Atherosclerosis. 2022;357:41-50.
    >> Share

    August 2022
  40. MICHIKURA M, Hori M, Ogura M, Hosoda K, et al
    The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
    Atherosclerosis. 2022;358:41-46.
    >> Share

  41. SVENDSEN K, Olsen T, Vinknes KJ, Mundal LJ, et al
    Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study.
    Atherosclerosis. 2022;358:34-40.
    >> Share

  42. MIZUTA MH, Santos RD
    Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Atherosclerosis. 2022 Aug 22. pii: S0021-9150(22)01389.
    >> Share

    July 2022
  43. MCKAY AJ, Gunn LH, Ray KK
    Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort.
    Atherosclerosis. 2022 Jul 21. pii: S0021-9150(22)01352.
    >> Share

    June 2022
  44. JAHN B, Santamaria J, Dieplinger H, Binder CJ, et al
    Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Atherosclerosis. 2022;355:15-29.
    >> Share

  45. TAMURA K, Kumagai T, Kobayashi K
    Possible clinical usefulness of polygenic risk scores among patients with established atherosclerotic cardiovascular disease.
    Atherosclerosis. 2022;350:100-101.
    >> Share

    May 2022
  46. CHEMELLO K, Chan DC, Lambert G, Watts GF, et al
    Recent advances in demystifying the metabolism of lipoprotein(a).
    Atherosclerosis. 2022;349:82-91.
    >> Share

  47. PEDERIVA C, Capra ME, Biasucci G, Banderali G, et al
    Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
    Atherosclerosis. 2022;349:233-239.
    >> Share

  48. RIDER DA, Eisermann M, Loffler K, Aleku M, et al
    Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
    Atherosclerosis. 2022;349:240-247.
    >> Share

    April 2022
  49. TENG H, Gao Y, Wu C, Zhang H, et al
    Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: Results from China PEACE Million Persons Project.
    Atherosclerosis. 2022;350:58-64.
    >> Share

    March 2022
  50. NOTO D, Spina R, Giammanco A, Barbagallo CM, et al
    Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.
    Atherosclerosis. 2022;347:63-67.
    >> Share

  51. MULDER JWCM, Kranenburg LW, Treling WJ, Hovingh GK, et al
    Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study.
    Atherosclerosis. 2022 Mar 12. pii: S0021-9150(22)00136.
    >> Share

    February 2022
  52. STOCK JK
    Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.
    Atherosclerosis. 2022 Feb 20. pii: S0021-9150(22)00077.
    >> Share

    January 2022
  53. PAQUETTE M, Baass A
    Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?
    Atherosclerosis. 2022;340:46-47.
    >> Share

    December 2021
  54. TRINDER M, Vikulova D, Pimstone S, Mancini GBJ, et al
    Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
    Atherosclerosis. 2021;340:35-43.
    >> Share

  55. TADA H, Okada H, Nohara A, Takamura M, et al
    Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;340:28-34.
    >> Share

    November 2021
  56. CHAKRABORTY A, Pang J, Chan DC, Ellis KL, et al
    Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).
    Atherosclerosis. 2021 Nov 12. pii: S0021-9150(21)01417.
    >> Share

  57. SANCHEZ-RAMOS A, Fernandez-Labandera C, Vallejo-Vaz A, Bonacho EC, et al
    Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study.
    Atherosclerosis. 2021;338:39-45.
    >> Share

  58. TROMP TR, Cupido AJ, Reeskamp LF, Stroes ESG, et al
    Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.
    Atherosclerosis. 2021 Nov 2. pii: S0021-9150(21)01413.
    >> Share

    October 2021
  59. LEONARDI-BEE J, Boateng C, Faria R, Eliman K, et al
    Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2021;338:7-14.
    >> Share

    September 2021
  60. STOCK JK
    Global Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2021 Sep 23. pii: S0021-9150(21)01361.
    >> Share

  61. PAQUETTE M, Bernard S, Baass A
    Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:41-46.
    >> Share

  62. KLEVMOEN M, Bogsrud MP, Retterstol K, Svilaas T, et al
    Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:8-15.
    >> Share

    August 2021
  63. MARCO-BENEDI V, Cenarro A, Laclaustra M, Larrea-Sebal A, et al
    Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Atherosclerosis. 2021 Aug 23. pii: S0021-9150(21)01270.
    >> Share

  64. DYRBUS K, Gasior M, Desperak P, Trzeciak P, et al
    Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
    Atherosclerosis. 2021;333:16-23.
    >> Share

  65. TOMBLING BJ, Zhang Y, Huang YH, Craik DJ, et al
    The emerging landscape of peptide-based inhibitors of PCSK9.
    Atherosclerosis. 2021;330:52-60.
    >> Share

    July 2021
  66. KATZMANN JL, Lehmann M, Tunnemann-Tarr A, An Haack I, et al
    Cutaneous manifestations in familial hypercholesterolaemia.
    Atherosclerosis. 2021 Jul 11. pii: S0021-9150(21)01236.
    >> Share

  67. KHALIL YA, Rabes JP, Boileau C, Varret M, et al
    APOE gene variants in primary dyslipidemia.
    Atherosclerosis. 2021;328:11-22.
    >> Share

  68. ALVES AC, Azevedo S, Benito-Vicente A, Graca R, et al
    LDLR variants functional characterization: Contribution to variant classification.
    Atherosclerosis. 2021;329:14-21.
    >> Share

    June 2021
  69. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    >> Share

  70. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    >> Share

  71. ROOS CM, Zhang B, Hagler MA, Arghami A, et al
    MnSOD protects against vascular calcification independent of changes in vascular function in hypercholesterolemic mice.
    Atherosclerosis. 2021 Jun 8. pii: S0021-9150(21)00276.
    >> Share

    May 2021
  72. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    >> Share

    April 2021
  73. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    >> Share

  74. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    >> Share

  75. SUADONI MT
    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.
    >> Share

  76. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    >> Share

  77. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    >> Share

    March 2021
  78. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
    >> Share

  79. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.
    >> Share

  80. BIESECKER LG
    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.
    >> Share

  81. ZIGMOND ZM, Song L, Martinez L, Lassance-Soares RM, et al
    c-Kit expression in smooth muscle cells reduces atherosclerosis burden in hyperlipidemic mice.
    Atherosclerosis. 2021 Mar 9. pii: S0021-9150(21)00112.
    >> Share

  82. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.
    >> Share

    February 2021
  83. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    >> Share

  84. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    >> Share

    January 2021
  85. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    >> Share

  86. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    >> Share

  87. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    >> Share

  88. GAUTIER T, Deckert V, Aires V, Le Guern N, et al
    Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits.
    Atherosclerosis. 2021;320:10-18.
    >> Share

  89. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    >> Share

  90. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.
    >> Share

  91. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.
    >> Share

    December 2020
  92. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    >> Share

  93. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    >> Share

  94. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    >> Share

  95. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    >> Share

    November 2020
  96. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    >> Share

  97. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    >> Share

    October 2020
  98. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    >> Share

    September 2020
  99. BURRIS RL, Vick SC, Popovic B, Fraungruber PE, et al
    Maternal exposure to soy diet reduces atheroma in hyperlipidemic F1 offspring mice by promoting macrophage and T cell anti-inflammatory responses.
    Atherosclerosis. 2020;313:26-34.
    >> Share

  100. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    >> Share

  101. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    >> Share

    May 2020
  102. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    >> Share

  103. DE NISCO G, Hoogendoorn A, Chiastra C, Gallo D, et al
    The impact of helical flow on coronary atherosclerotic plaque development.
    Atherosclerosis. 2020;300:39-46.
    >> Share

    March 2020
  104. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    >> Share

    February 2020
  105. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    >> Share

    January 2020
  106. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016